Analysts' Revenue Estimates For Innate Pharma S.A. (EPA:IPH) Are Surging Higher

Innate Pharma S.A. (EPA:IPH) shareholders will have a reason to smile today, with the analysts making substantial upgrades to this year's statutory forecasts. The revenue forecast for this year has experienced a facelift, with analysts now much more optimistic on its sales pipeline.

Following the latest upgrade, the current consensus, from the six analysts covering Innate Pharma, is for revenues of €43m in 2023, which would reflect a considerable 18% reduction in Innate Pharma's sales over the past 12 months. Before the latest update, the analysts were foreseeing €38m of revenue in 2023. It looks like there's been a clear increase in optimism around Innate Pharma, given the nice gain to revenue forecasts.

See our latest analysis for Innate Pharma

Taking a look at the bigger picture now, one of the ways we can understand these forecasts is to see how they compare to both past performance and industry growth estimates. One more thing stood out to us about these estimates, and it's the idea that Innate Pharma's decline is expected to accelerate, with revenues forecast to fall at an annualised rate of 33% to the end of 2023. This tops off a historical decline of 14% a year over the past five years. Compare this against analyst estimates for companies in the broader industry, which suggest that revenues (in aggregate) are expected to grow 25% annually. So it's pretty clear that, while it does have declining revenues, the analysts also expect Innate Pharma to suffer worse than the wider industry.

The Bottom Line

The highlight for us was that analysts increased their revenue forecasts for Innate Pharma this year. They also expect company revenue to perform worse than the wider market. Seeing the dramatic upgrade to this year's forecasts, it might be time to take another look at Innate Pharma.

Looking to learn more? At least one of Innate Pharma's six analysts has provided estimates out to 2025, which can be seen for free on our platform here.

Of course, seeing company management invest large sums of money in a stock can be just as useful as knowing whether analysts are upgrading their estimates. So you may also wish to search this free list of stocks that insiders are buying.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.